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Strengths and limitations of this study
 ► This is the first randomised trial of corneal cross-link-
ing (CXL) in keratoconus in children, in which group 
disease onset is at an early age, is perceived to be 
at high risk of progression to corneal transplantation 
and in which only observational studies have been 
published.
 ► A total of 60 patients aged 10–16 years with pro-
gressive keratoconus will be randomised to CXL 
or standard care including spectacles and contact 
lenses as required for best-corrected vision.
 ► The trial is designed to examine safety and efficacy 
of CXL in reducing progression, the primary outcome 
measure being between-group difference in K2 at 18 
months adjusted for K2 at baseline examination and 
measured by masked optometrists.
 ► Secondary outcome measures at 18 months include 
keratoconus progression, visual acuity, refraction, 
adverse events and quality of life measurements.
 ► Follow-up to 18 months after randomisation is rel-
atively short and any benefit found following CXL 
would require longer term analysis of efficacy.
AbStrACt
Introduction The KERALINK trial tests the hypothesis 
that corneal cross-linking (CXL) treatment reduces the 
progression of keratoconus in comparison to standard 
care in patients under 17 years old. KERALINK is a 
randomised controlled, observer-masked, multicentre trial 
in progressive keratoconus comparing epithelium-off CXL 
with standard care, including spectacles or contact lenses 
as necessary for best-corrected acuity.
Methods and analysis A total of 30 participants will be 
randomised per group. Eligible participants aged 10–16 
years with progressive keratoconus in one or both eyes 
will be recruited. Following randomisation, participants 
will be followed up 3-monthly for 18 months. The effect 
on progression will be determined by K
2 on corneal 
topography. The primary outcome measure is between-
group difference in K2 at 18 months adjusted for K2 at 
baseline examination. Secondary outcomes are the 
effect of CXL on (1) keratoconus progression, (2) time to 
keratoconus progression, (3) visual acuity, (4) refraction, 
(5) apical corneal thickness and (6) adverse events. 
Patient-reported effects will be explored by questionnaires.
Ethics and dissemination Research Ethics Committee 
Approval was obtained on 30 June 2016 (ref: 14/LO/1937). 
Current protocol: V.5.0 (08/11/2017). Study findings will be 
published in peer-reviewed journals.
trial registration number European Union clinial trials 
register (EudraCT) 2016-001460-11
IntroduCtIon
Keratoconus is characterised by thinning 
and distortion of the cornea that results in 
visual loss from complex refractive error 
and corneal opacification. The prevalence 
in Europe has been reported as 1:11631 and 
1:375.2 The age at initial referral to hospital 
clinics is the second and third decade (mean 
age at diagnosis 28 years2), with progression 
until the early 30s in most affected eyes. In its 
early stages, keratoconus causes worsening of 
vision on account of increasing myopia and 
irregular astigmatism: spectacle correction 
provides good visual acuity in early disease 
only, until increasing irregular astigmatism 
requires correction with rigid contact lenses 
for best vision. Patients with more advanced 
keratoconus lose contact lens-corrected visual 
acuity on account of corneal opacification 
and corneal transplant surgery is eventually 
required in >20% of patients.3 Keratoconus 
is often more advanced when first diagnosed 
in children than in adults, with faster subse-
quent disease progression.4
The most important parameters used in 
the assessment of keratoconus are the curva-
ture of the cornea (presented as dioptre 
power (D)), apical corneal thickness in µm, 
refraction and best-corrected visual acuity. 
Earliest disease can be detected by corneal 
topography, which demonstrates thinning 
and irregularity of corneal curvature. Quanti-
fication of steepness of the corneal curvature 
in horizontal, vertical and multiple oblique 
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meridians identifies the meridian of maximum corneal 
steepness (K2) and the point of maximum steepness 
(Kmax).
While the standard care described above involves treat-
ment of the refractive consequences of keratoconus 
or replacement of the diseased cornea by a transplant, 
the concept of stabilising keratoconus and arresting its 
progression at a stage when there is still good unaided 
or spectacle-corrected vision is relatively recent. Corneal 
cross-linking (CXL) increases the stiffness of the cornea, 
which can arrest the progression of early keratoconus.5 
It is the only current intervention for this purpose. 
In the epithelium-off CXL procedure corneal epithe-
lium is removed, riboflavin eye drops administered and 
the cornea exposed to ultraviolet (UV) light for 8 or 
more minutes. CXL has been reported to be effective 
in arresting keratoconus progression in the majority of 
treated adult eyes in a number of non-randomised studies 
(including Henriquez et al,6 Hersh et al7) and randomised 
controlled trials (RCTs) (O’Brart et al,8 Wittig-Silva et al.9). 
In the larger study by Wittig-Silva et al, a significant differ-
ence in progression of corneal power in the steepest axis 
(termed ‘Kmax’ by these authors but in later publications 
widely designated ‘K2’) between CXL and control eyes was 
reported: an improvement in CXL-treated eyes with flat-
tening of Kmax by −1.03±0.19 D compared with an increase 
in Kmax for control eyes of +1.75 ± 0.38 D at 36 months. 
Adverse effects were not uncommon but mostly transient, 
including corneal oedema, superficial opacification and 
recurrent corneal erosions. Despite increasing informa-
tion in relation to the efficacy of CXL a Cochrane Review 
conducted in 2015 concluded that evidence for the use of 
CXL in the management of keratoconus is limited due to 
the lack of properly conducted RCTs.10
In younger subjects, a number of observational studies 
of CXL in keratoconus patients <19 years have been 
published, each with limitations but each reporting effec-
tiveness. Caporossi et al reported an uncontrolled study 
of 152 keratoconus patients ranging in age from 10 to 
18 years, of whom follow-up post-CXL was available on 
only 61% of patients.11 Inclusion criteria included several 
parameters which are well recognised to be character-
ised by intertest variability. In this treated patient group, 
a statistically significant reduction of Kmax by −0.4 D was 
found. Vinciguerra et al reported 40 CXL-treated eyes in 
patients with progressive keratoconus aged 9–18 (mean 
14.2) years in a non-randomised prospective study.12 Find-
ings included improved visual acuity, reduced myopic 
spherical equivalent on refraction testing and flattening 
on keratometry readings compared with pre-CXL. Good-
frooij et al reported progression in 22% within 5 years of 
CXL.13 Although the findings from these studies suggested 
a beneficial effect of CXL, more robust evidence is 
required to inform practice. Of note, no randomised trial 
has been undertaken in young patients. The KERALINK 
trial has been designed to investigate efficacy and safety 
of the established technique of CXL in progressive kera-
toconus in the paediatric age group, in which on account 
of early disease onset there is such potential for kerato-
conus progression. This paper describes the design of 
the trial, which compares progression of keratoconus in 
a population of children and young patients randomised 
to CXL or standard care, and evaluates safety of the inter-
vention in this patient group.
Evidence of effectiveness of CXL is of particular 
interest in young patients and has specifically been 
requested by the National Institute for Health and Care 
Excellence in the UK. KERALINK is a multicentre RCT 
in this patient group evaluating epithelium-off CXL, 
the technique of CXL which has been demonstrated to 
be effective in adults. If the trial demonstrates efficacy 
of CXL compared with standard care, and in particular 
if CXL is arrests keratoconus progression, this would 
have important implications for clinical management. 
Although we intend to follow-up the trial patients for 
several years after the proposed trial concludes in order 
to ascertain the duration of keratoconus stability, it is 
clear that arrested progression in a paediatric patient is 
likely (1) to obviate the need for contact lens correction 
and for later corneal transplant surgery and (2) to have 
correspondingly greater health and cost benefit than if 
the CXL were undertaken in adults. Trial findings will 
inform ophthalmologists, optometrists and inform future 
research and treatment policy.
MEthodS And AnAlySIS
Study design
KERALINK is a randomised controlled, observer-masked 
controlled trial in five centres in the UK. The study 
adheres to the tenets of the Declaration of Helsinki and 
is registered at www. controlled- trials. com and the Euro-
pean Union clinical trials registry. It was approved by 
the UK Health Research Authority, the Medicines and 
Healthcare Regulatory Agency and ethical approval was 
granted by the Brent Ethics Committee (reference 16/
LO/0913). The trial is supervised by a trial manage-
ment group (TMG), with independent oversight by a 
trial steering committee (TSC) and a data monitoring 
committee. Eligible patients are randomised in a 1:1 ratio 
to receive either CXL or standard care including specta-
cles or contact lenses as necessary (standard care of early 
keratoconus in the UK includes correction of refractive 
error and not CXL). Following randomisation, partici-
pants are followed for 18 months at 3-monthly intervals. 
Inclusion and exclusion criteria are shown in table 1. 
All follow-up measurements are performed by masked 
observers (optometrists) and the treating ophthalmolo-
gists are masked as to keratometry values on topography 
at follow-up. Randomisation commenced on 31 October 
2016 and follow-up of the last recruited patient is esti-
mated to complete in mid-2020.
definition of progression for eligibility
To differentiate true keratoconus progression from 
measurement artefact or minimal progression, an 
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Table 1 KERALINK inclusion and exclusion criteria
Inclusion 
criteria
Age at randomisation: 10–16 years
Confirmed keratoconus diagnosis
Progression on Pentacam topography in 
one or both eyes, steepest corneal meridian 
(K2) or Kmax>1.5 D
Exclusion 
criteria
Apical scarring
Cone apex thickness <400 µm
K2 >62.0 D or Kmax >70.0 D
Rigid lens wear in both eyes and unable 
to abstain for 7 days pretopography 
examinations
Down’s syndrome
Figure 1 KERALINK: efficacy and safety of cross-linking in 
children with keratoconus.
increase on topography (Pentacam, Oculus GmbH, 
Wetzlar, Germany) in the steepest keratometry (Kmax) or 
in the steepest corneal meridian (K2) of at least 1.5 D was 
used as threshold for eligibility in one or both eyes. Based 
on this, eligibility was defined by an increase from base-
line in Kmax or K2 of >1.5 D between two topography exam-
inations separated by 3 or more months. For each patient, 
the eye with the more advanced keratoconus at baseline 
will be categorised as the study eye for the primary anal-
ysis, unless that eye had undergone prior surgery such as 
corneal transplantation.
baseline assessment
At baseline all patients will be assessed as follows.
On these visits the following assessments will be 
performed.
1. Corneal topography for measurement of corneal pow-
er in the steepest meridian (K2), used for assessment of 
the primary outcome. To improve repeatability, three 
measurements of each eye will be taken at baseline and 
follow-up examinations and the mean used in compar-
isons. Contact lenses will be removed at least 7 days 
prior to topography.
2. Visual acuity (unaided, spectacle-corrected and con-
tact lens-corrected as applicable), logMAR measured 
using the Early Treatment Diabetic Retinopathy Study 
(ETDRS) chart at a starting distance of 4 m in both 
eyes.
3. Subjective refraction, both eyes
4. Apical corneal thickness measurement, both eyes, by 
ultrasound and Scheimpflug imaging at topography
5. Quality of life will be assessed by visual function (Cardiff 
Visual Ability Questionnaire for Children (CVAQC) 
and generic paediatric health outcome (Child Health 
Utility 9D (CHU9D) questionnaires. CVAQC is a 25-
item vision-specific questionnaire designed for chil-
dren.14 CHU9D is a nine-question paediatric generic 
preference-based measure of health outcome which 
provides a descriptive health profile as well as a utility 
score and has been validated for self-completion in an 
adolescent population (11–17 years).15
randomisation and allocation of participants to treatment 
groups
Randomisation will be by a centralised computer-gener-
ated randomisation service (https://www. sealedenvelope. 
com). The system is customised to trial requirements, 
using minimisation with stratification by treatment centre 
and whether progression is confirmed in one eye or both 
eyes at randomisation. Following a dedicated consent/
screening and randomisation visit for eligible patients 
and their parents, patients will be randomised to one of 
two trial arms (figure 1). Specific study information sheets 
will be provided to parents and patients prior to taking 
consent; a parent or guardian will be asked to provide 
consent in all cases and patients aged 15–16 years will be 
asked to provide assent if this is their choice.
Intervention: CXl
Corneal cross-linking in one or both eyes (according to 
whether progression is confirmed in one eye or both), 
under general or local anaesthesia as applicable, followed 
by standard management. The surgical procedure will be 
as follows: insertion of lid speculum, removal of corneal 
epithelium with a spatula, administration of riboflavin 
drops (Vibex Rapid, Avedro, Waltham, Massachusetts, 
USA) every 2 min for 10 min, application of pulsed UV 
light using standardised parameters of 10 mW/cm2 for 
a 5.4 J/cm2 total energy dose administered over 8 min 
in a pulsed manner (Avedro KXL). At completion of 
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the procedure one drop of povidone iodine and a ther-
apeutic contact lens will be applied to the treated eye. 
Management post-CXL is (1) proxymetacaine drops 
every 2 hours and naproxen 250 mg two times per day, 
both as required for analgesia, (2) moxifloxacin 0.5% 
drops every 6 hours for 1 week as infection prophylaxis, 
(3) dexamethasone 0.1% drops every 6 hours for 1 week, 
every 12 hours for 1 week, then fluorometholone 0.1% 
drops every 12 hours for 1 week. Patients randomised 
to CXL will attend for an extra examination at 1 week 
post-CXL for removal of the contact lens and confirma-
tion of corneal re-epithelialisation.
Comparator: standard care
The trial control arm is standard management alone, 
including refraction testing with provision of glasses and/
or contact lens fitting for one or both eyes as required for 
best-corrected visual acuity.
defining keratoconus progression for secondary outcomes
To differentiate true keratoconus progression from 
measurement artefact, we will define progression as an 
increase in power in the steepest corneal meridian (K2) 
of >1.5 D on corneal topography between two exam-
inations or the requirement for change from spectacle 
to rigid contact lenses correction of vision, as the latter 
precludes reliable topography measurements.
outcome measures
The primary trial outcome measure will be between-
group difference in K2 at 18 months adjusted for K2 at 
baseline examination.
Secondary outcomes will be the effect of CXL on
1. Keratoconus progression (yes/no) defined as >1.5 
D increase from baseline in K2, confirmed at subse-
quent visits or keratoconus progression requiring 
change from spectacle to rigid contact lens correc-
tion of vision, which precludes reliable topography 
measurements
2. Time to keratoconus progression.
3. Uncorrected and best-corrected visual acuity (log-
MAR) measured with an ETDRS chart at a starting dis-
tance of 4 m.
4. Refraction (measured dioptres spherical equivalent, 
myopia and astigmatism).
5. Apical corneal thickness.
6. Quality of life as assessed by paediatric health outcome 
and visual function questionnaires.
trial duration
All patients will be assessed at baseline, 3, 6, 9, 12, 15 and 
18 months. Any patient found to have >1.5 D increase in 
K2 will need to have this confirmed at a subsequent visit 
(ie, 3 months later). Participants who have unconfirmed 
progression at the 18-month follow-up visit will need this 
confirmed at a further visit at 21 months.
Adverse events
Patients will be assessed for adverse events at the 
1 week post-CXL follow-up and at all visits following 
randomisation.
1. Any reversible or short-term corneal abnormality, for 
example, prolonged eye pain, delayed corneal epithe-
lialisation, transient corneal oedema.
2. Any visually significant corneal abnormality, for exam-
ple, opacity resulting from sterile inflammatory infil-
trates, corneal infection or stromal melting.
3. Any untoward medical occurrence in a study patient 
which does not necessarily have a causal relationship 
with the treatment under study, for example, abnormal 
laboratory findings, or disease symptoms and signs.
The Independent Data Monitoring Committee (IDMC) 
will monitor adverse events and serious adverse events 
during the trial to inform their recommendations to the 
TSC. Participants in the standard care arm with significant 
progression confirmed at two successive examinations 
will be considered for other keratoconus management 
options including cross-over to CXL
Sample size calculation
The primary outcome is K2 at 18 months, adjusted for K2 
at baseline, in the study eye recorded by an optometrist 
masked to the treatment group. A difference between the 
groups in the change in K2 of >1.5 D from randomisation 
to 18 months is considered to be a clinically important 
difference (based on Wittig-Silva et al9). A K2 increase 
>1.5 D would discriminate a true change in the steepest 
corneal meridian from measurement artefact and would 
be visually significant. A sample size of 46 patients would 
be required to detect this difference at the 5% signifi-
cance level with 90% power, assuming a SD of 1.5 D. The 
total sample size has been increased to 60 patients (30 
per group) to allow for up to 24% loss to follow-up. These 
estimates are based on 12-month and 24-month data 
reported by Wittig-Silva et al from which we estimated a 
pooled SD of the changes of 1.476 D. We expect that on 
average there will be 10% loss to follow-up in both groups. 
In the study by Wittig-Silva et al, 19% of patients withdrew, 
crossed over to CXL or had a transplant by 18 months. 
However, 18% of patients in the control group either 
received CXL or a transplant. If we specifically adjust the 
sample size to take account of 10% loss to follow-up and 
up to 20% of the control arm cross-over to CXL or trans-
plant, then our planned total sample size of 60 patients 
would still provide at least 80% power to detect the clin-
ically important difference. The trial protocol states that 
participants cannot cross over to CXL before 9 months.
Patient and public involvement
Patients and parents were first involved in this research 
at a patient event hosted by Moorfields Eye Hospital. 
Topics on which opinions were collected included rando-
misation, cross-over and the duration of follow-up of trial 
patients. The research questions, design and trial outcome 
measures in the protocol were finalised following the 
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above meeting and additional input from the UK Kera-
toconus Self-Help and Support Association. This Associ-
ation supported the trial by publicising the trial and by 
providing representatives on the TMG and the trial IDMC. 
The investigators will communicate a summary of the trial 
results to participants and their parents. The UK Kerato-
conus Self Help and Support Association will disseminate 
in their website and other communications the results to 
keratoconus patients. The burden of the intervention was 
discussed at our initial meeting with patients and parents 
and at the consent-taking stage in the trial.
Statistical analysis plan
The primary analysis will be conducted following the 
intention-to-treat (ITT) principle where all randomised 
patients will be analysed in their allocated group whether 
or not they receive their allocated treatment. Patient 
characteristics at the time of randomisation will be 
summarised using mean and SD for continuous variables 
which are approximately normally distributed, median 
and IQR for variables which are not normally distrib-
uted, or by frequencies and percentages for categorical 
variables. All statistical tests will use a two-sided p value 
of 0.05 unless otherwise specified. All CIs presented will 
be 95% and two-sided. A detailed statistical analysis plan 
will be developed for approval by the TSC and review by 
the IDMC and finalised before the first statistical anal-
ysis of unmasked outcome measures. No formal interim 
analysis is planned, but reports concerning patient safety 
and key efficacy outcomes will be prepared for regular 
review by the IDMC who may request an interim analysis 
if a report raises concern. The IDMC is independent from 
the sponsor and funders. The membership, frequency 
of meetings, activity (including trial conduct and data 
review) and authority will be covered in the UCL CCTU 
IDMC terms of reference.
For each patient, the eye with the more advanced kera-
toconus at the time of randomisation will be defined as 
the study eye for the primary analysis, unless that eye 
has previously been treated by CXL or corneal trans-
plantation. The analysis of the primary outcome will 
be performed using a linear mixed model fitted to all 
K2 values recorded after randomisation. K2 at randomi-
sation, treatment group, follow-up time, the interaction 
between treatment and time, and the stratifying variables 
centre and whether each patient has one or both eyes 
eligible will be included as fixed effects. A random patient 
effect will be included to take account of clustering by 
patient. The regression coefficient for treatment group 
in this model estimates the difference between the mean 
changes in K2 of each group.
16 Model assumptions will be 
assessed, and a logarithmic transformation may be used 
if this improves normality of the residuals. In the event 
of substantial (>10%) cross-over from the randomised 
arm to the other arm, we will perform two analyses of the 
primary outcome, the primary ITT analysis and a per-pro-
tocol analysis. The per-protocol analysis will exclude any 
information collected from a patient after cross-over. 
Any cross-over or other treatment deviations will be 
summarised with reasons.
An ITT analysis will be performed for all secondary 
outcomes. Secondary continuous outcomes such as uncor-
rected and best-corrected visual acuity measured at rando-
misation and on more than one occasion during follow-up 
will be analysed using similar linear mixed models. Uncor-
rected and best-corrected visual acuity will be measured 
in logMAR using an ETDRS chart at a distance of 4 m. In 
patients for whom both eyes show progression at the time of 
randomisation, information from both eyes will be included 
in a secondary analysis including eye as a fixed effect and 
patient as a random effect.
Fisher’s exact test will be used to compare the proportion 
of study eyes with keratoconus progression in each treat-
ment group. Cox regression analysis will be used to estimate 
time to keratoconus progression in the study eye for each 
treatment group. The model will adjust for the stratifying 
variables, centre and whether each patient has one or both 
eyes eligible. Patients who do not progress during the course 
of the trial will be censored at their last follow-up visit.
We will also explore how visual disability and health in 
children and young patients with keratoconus relate to 
changes in K2. The impact of missing data will be miti-
gated against by incorporating information from all 
observed time points using a mixed model approach.
Planned subgroup analyses will be conducted to inves-
tigate whether the effect of CXL differs between patients 
who had progression at randomisation in one or both 
eyes. This will be explored by adding an interaction 
between the number of eyes with progression at rando-
misation and CXL treatment to the primary efficacy 
outcome analysis mixed model.
EthICS And dISSEMInAtIon
Ethical and safety considerations
The trial was approved by the UK Health Research Authority 
and the Medicines and Healthcare Regulatory Agency. 
Trial investigators will ensure that the study (including any 
approved amendments) is conducted in accordance with 
the principles of the Declaration of Helsinki.
dissemination plan
The results of the trial will be reported in accordance with 
Consolidated Standards of Reporting Trials guidance and 
will be disseminated regardless of the direction of effect. 
Publications generated from the trial will be attributed 
to the TMG, which consists of all those who have whole-
heartedly collaborated in the trial. The main report will be 
drafted by the TMG, and the final version will be reviewed 
by the TSC before submission for publication. Trial find-
ings will be disseminated to the patients, UK Keratoconus 
Self-Help and Support Group and also doctors, optome-
trists, advisory bodies and healthcare commissioners. This 
will take the form of papers in peer-reviewed open-access 
medical journals and presentations at conferences.
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